TMO Stock Recent News
TMO LATEST HEADLINES
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.
The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Thermo Fisher Scientific (TMO) reported better second-quarter earnings than analysts had expected Wednesday, and also raised its projections for the full fiscal year.
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.37 per share, beating the Zacks Consensus Estimate of $5.13 per share. This compares to earnings of $5.15 per share a year ago.
Thermo Fisher on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials.
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Medical Refrigerators - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Medical Refrigerators is estimated at US$4.4 Billion in 2023 and is projected to reach US$7.1 Billion by 2030, growing at a CAGR of 6.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Key Insights:
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.
Stocks tend to sell off after they reach resistance. They also tend to rally off of support.
Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.